Abiomed's Impella PMA approval 'all but secured'
This article was originally published in Clinica
Executive Summary
Abiomed’s share price shot up 24% after news that US FDA approval of its percutaneous heart pump Impella is “all but secured,” according to Jefferies analyst Raj Denhoy. The company announced that it and the agency have agreed that Impella 2.5 should be indicated for high-risk percutaneous coronary intervention (PCI), paving the way for premarket approval (PMA). Importantly, Abiomed added that based on its discussions with this FDA, the company could expect to leapfrog the FDA advisory panel before final approval of Impella; Abiomed is expecting approval by February/March 2015.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.